Mono Pharmacare

When is the next results date for Mono Pharmacare?

No Upcoming Board Meetings

Has Mono Pharmacare declared dividend?

No Dividend History Available

What is the technical trend for Mono Pharmacare?

As of May 19, 2025, Mono Pharmacare's technical trend is mildly bearish, indicated by daily moving averages and monthly Bollinger Bands, despite some conflicting signals from weekly MACD and KST.

As of 19 May 2025, the technical trend for Mono Pharmacare has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish, suggesting some conflicting signals. The Bollinger Bands show a bearish trend on the monthly timeframe, further supporting the bearish outlook. The stock has experienced a significant decline year-to-date and over the past year, underperforming compared to the Sensex. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the monthly Bollinger Bands.

Who are the peers of the Mono Pharmacare?

Mono Pharmacare's peers include Medicamen Organ., Vilin Bio Med, ANG Lifesciences, Veerhealth Care, Chandra Bhagat, Guj. Terce Labs., Roopa Industries, Kabra Drugs, and Shree Ganesh Bio. In terms of performance, Vilin Bio Med has the highest 1-year return at 34.25%, while Mono Pharmacare's return is -34.38%.

Peers: The peers of Mono Pharmacare are Medicamen Organ., Vilin Bio Med, ANG Lifesciences, Veerhealth Care, Chandra Bhagat, Guj. Terce Labs., Roopa Industries, Kabra Drugs, and Shree Ganesh Bio.<BR><BR>Quality Snapshot: Excellent management risk is observed at Medicamen Organ., while Below Average management risk is found at Mono Pharmacare, Vilin Bio Med, ANG Lifesciences, Veerhealth Care, Chandra Bhagat, Guj. Terce Labs., Roopa Industries, and Shree Ganesh Bio. Growth is Excellent at Medicamen Organ., Good at Mono Pharmacare, and Below Average at Vilin Bio Med, ANG Lifesciences, Veerhealth Care, Chandra Bhagat, Guj. Terce Labs., Roopa Industries, and Shree Ganesh Bio. Capital Structure is Good at Veerhealth Care, Below Average at Medicamen Organ., Mono Pharmacare, Vilin Bio Med, ANG Lifesciences, Chandra Bhagat, Guj. Terce Labs., Roopa Industries, and Shree Ganesh Bio, while Kabra Drugs does not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Vilin Bio Med at 34.25%, while the peer with the lowest is Medicamen Organ. at -63.92%. Mono Pharmacare's own 1-year return is -34.38%, which is better than Medicamen Organ. but worse than Vilin Bio Med. Additionally, the six-month return is negative for Mono Pharmacare and Medicamen Organ.

What does Mono Pharmacare do?

Mono Pharmacare Ltd is a Micro Cap company focused on marketing and distributing pharmaceutical products. It transitioned from a partnership to a public limited company in October 2022, with a market cap of INR 43 Cr and key metrics including a P/E ratio of 14.00.

Overview: <BR>Mono Pharmacare Ltd is engaged in the marketing and distribution of pharmaceutical products and operates within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History: <BR>Mono Pharmacare Limited was originally formed as a Partnership Firm named "M/s. Mono Chemist" on May 06, 1994. It was converted into a Public Limited company on October 17, 2022, as per the Certificate of Incorporation issued by the Registrar of Companies, Ahmedabad. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 43 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 14.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.46 <BR>Return on Equity: 10.99% <BR>Price to Book: 1.53 <BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: Not available <BR>Email: Not available <BR>Website: Not available

Who are the top shareholders of the Mono Pharmacare?

The top shareholder of Mono Pharmacare is Lakhatariya Panilam, holding 45.43% of the shares. The highest public shareholder is Harshad Rasiklal Sheth at 3.68%, while individual investors collectively own 35.6%.

The top shareholders of Mono Pharmacare include the promoters, with Lakhatariya Panilam holding the largest share at 45.43%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors do not hold any shares in the company. The highest public shareholder is Harshad Rasiklal Sheth, who owns 3.68%. Additionally, individual investors collectively hold 35.6% of the shares.

How big is Mono Pharmacare?

As of 23rd July, Mono Pharmacare Ltd has a market capitalization of 42.00 Cr, classifying it as a Micro Cap company. The latest financial data for the past four quarters is unavailable, but for the annual period ending March 2024, it reports Shareholder's Funds of 28.11 Cr and Total Assets of 81.10 Cr.

As of 23rd July, Mono Pharmacare Ltd has a market capitalization of 42.00 Cr, categorizing it as a Micro Cap company.<BR><BR>There is no valid financial data available for the latest four quarters, including Net Sales and Net Profit figures.<BR><BR>For the latest annual period ending in March 2024, the company reports Shareholder's Funds of 28.11 Cr and Total Assets of 81.10 Cr.

Is Mono Pharmacare overvalued or undervalued?

As of November 10, 2025, Mono Pharmacare is considered overvalued with a valuation grade of expensive, reflected by its PE Ratio of 11.72 and underperformance of 43.84% compared to the Sensex's 5.91% gain, especially when compared to peers like Sun Pharma and Cipla.

As of 10 November 2025, the valuation grade for Mono Pharmacare has moved from very expensive to expensive. The company is currently considered overvalued based on its financial ratios. Key ratios include a PE Ratio of 11.72, an EV to EBITDA of 11.68, and a PEG Ratio of 0.44, which indicates potential growth at a reasonable price compared to its earnings.<BR><BR>When comparing Mono Pharmacare to its peers, Sun Pharma has a significantly higher PE Ratio of 35.15, while Cipla, which is rated attractive, has a PE Ratio of 22.45. This suggests that Mono Pharmacare's valuation is not justified when looking at the broader industry context, especially given its recent stock performance, which has underperformed the Sensex over the past year, with a decline of 43.84% compared to the Sensex's gain of 5.91%.

How has been the historical performance of Mono Pharmacare?

Mono Pharmacare exhibited strong financial growth from March 2024 to March 2025, with net sales rising from 122.34 Cr to 168.34 Cr and profit after tax increasing from 2.46 Cr to 3.11 Cr, despite ongoing negative cash flow from operating activities. Total liabilities and debt also increased, but current assets improved, indicating better liquidity.

Answer:<BR>The historical performance of Mono Pharmacare shows a positive trend in key financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Mono Pharmacare's net sales increased significantly from 122.34 Cr in March 2024 to 168.34 Cr in March 2025, reflecting a robust growth in total operating income, which also rose to 168.34 Cr from 122.34 Cr. The total expenditure, excluding depreciation, rose to 160.71 Cr from 116.01 Cr, primarily driven by higher purchases of finished goods and other expenses. Operating profit, excluding other income, improved to 7.63 Cr from 6.33 Cr, leading to an overall operating profit of 8.61 Cr compared to 6.43 Cr the previous year. Profit before tax increased to 4.46 Cr from 3.23 Cr, and profit after tax rose to 3.11 Cr from 2.46 Cr. The consolidated net profit also saw an increase to 3.09 Cr from 2.44 Cr, with earnings per share growing to 1.75 from 1.38. On the balance sheet, total liabilities increased to 110.01 Cr from 81.10 Cr, with total debt rising to 53.56 Cr from 41.44 Cr. Current assets also grew significantly to 108.99 Cr from 80.16 Cr, indicating improved liquidity. However, cash flow from operating activities remained negative at -4.00 Cr, though it was an improvement from -8.00 Cr the previous year. Overall, Mono Pharmacare demonstrated strong revenue growth and profitability improvements, despite challenges in cash flow management.

Which are the latest news on Mono Pharmacare?

Why is Mono Pharmacare Ltd falling/rising?

As of 12-Feb, the stock price of Mono Pharmacare Ltd is at 11.90, unchanged from the previous session. Despite a recent 9.68% rise over the past week, the stock has declined 9.85% in the last month and 52.87% over the past year, indicating significant underperformance compared to the Sensex.

As of 12-Feb, the stock price of Mono Pharmacare Ltd is currently at 11.90, showing no change from the previous trading session. Over the past week, the stock has experienced a significant rise of 9.68%, which is notably higher than the Sensex's increase of 0.64% during the same period. However, when looking at the longer-term performance, the stock has declined by 9.85% over the past month and has a year-to-date drop of 21.71%. <BR><BR>In the past year, the stock has fallen dramatically by 52.87%, contrasting sharply with the Sensex, which has risen by 11.98%. This indicates a prolonged period of underperformance compared to the broader market. <BR><BR>Today's trading performance is described as inline with the sector, but there are concerning signs regarding investor participation. The delivery volume on 11 February was 6,000 shares, which represents a significant decline of 85.15% compared to the 5-day average delivery volume. This drop in investor participation could indicate a lack of confidence or interest in the stock, which may contribute to its overall downward trend in the longer term.<BR><BR>Additionally, while the stock is currently trading above its 5-day and 20-day moving averages, it remains below its 50-day, 100-day, and 200-day moving averages, suggesting that the stock may not be in a strong upward momentum despite the recent short-term gains. The liquidity of the stock is also noted to be adequate for trading, but the overall sentiment appears to be cautious given the falling investor participation.